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Abstract
Aldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous
aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and
detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene ampliﬁcation or mRNA
upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted
chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative
advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with
DIMATE, an irreversible inhibitor of ALDH1/3. DIMATE showed cytotoxicity in 73% of NSCLC cell lines tested and
demonstrated antitumor activity in orthotopic xenografts via hydroxynonenal-protein adduct accumulation, GSTO1-
mediated depletion of glutathione and increased H2O2. Consistent with this result, ALDH1/3 disruption synergized with
ROS-inducing agents or glutathione synthesis inhibitors to trigger cell death. In lung cancer xenografts with high to
moderate cisplatin resistance, combination treatment with DIMATE promoted strong synergistic responses with tumor
regression. These results indicate that NSCLCs with increased expression of ALDH1A1, ALDH1A3, or ALDH3A1 may be
targeted by strategies involving inhibitors of these isoenzymes as monotherapy or in combination with chemotherapy to
overcome patient-speciﬁc drug resistance.
Introduction
The aldehyde dehydrogenase (ALDH) family is a super-
family of intracellular enzymes that oxidize numerous
diverse physiologically and pathophysiologically relevant
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aldehydes to their corresponding nontoxic carboxylic acids
[1, 2]. Whereas ALDH family members play primarily
cytoprotective biological roles via detoxiﬁcation of alde-
hydes, they also modulate cell proliferation, differentiation
and survival [3, 4].
In nonsmall cell lung cancer (NSCLC), which accounts
for 85% of lung cancers, increasing evidence suggests that
ALDHs play functional roles in tumorigenicity and drug
resistance. Class 1 ALDH expression was found to correlate
with invasive properties, chemoresistance and the in vivo
ability to recapitulate original NSCLC [5, 6]. Activity of
these enzymes was also reported to correlate with Notch
expression, which drives a signaling pathway with altera-
tions in ~30% of NSCLCs [7]. The STAT3-NF-ĸB/DDIT3/
CEBPβ axis, one of the key oncogenic drivers in NSCLC,
was found to regulate ALDH1A3 expression [8, 9]. More
recent data indicated that stem cells located in airways may
initiate cancer formation and cause the poor clinical out-
come of NSCLC [10]. Notably, a main approach to isolate
these tumor-initiating cells was based on their increased
ALDH activity [11, 12].
The involvement of ALDHs in tumor initiation, ther-
apeutic resistance, and malignant behavior has been exten-
sively described in the literature [11–16]; however, the
identity and therapeutic value of the speciﬁc isoform(s)
contributing to these effects in particular tumor types—
including lung cancer—remains largely elusive, partially
due to the dearth of speciﬁc inhibitors and the mis-
interpretation of the extensively used ALDEFLUOR assay
[17–22].
Here, we conducted a meta-analysis to identify ALDH
isoforms with clinical and prognostic value in NSCLC.
Using genetic and pharmacological targeting approaches, we
showed that simultaneous inhibition of class 1 and class 3
ALDHs compromises glutathione (GSH) homeostasis. This
condition ultimately results in severe oxidative damage and
cell death. Finally, we demonstrated in vitro and in vivo that
are independent of EGFR and KRAS status, ALDH1 and
ALDH3 may be key therapeutic targets for NSCLC either
alone or combined with ROS-inducing chemotherapeutic
agents.
Results
Increased expression of ALDH1A1, ALDH1A3, or
ALDH3A1 in NSCLC impacts chemotherapeutic
responses and patient survival
First, we searched for alterations in the expression of genes
of the ALDH family in the two major histopathological
subtypes of NSCLC, lung adenocarcinoma (ADC) and
squamous cell carcinoma (SCC), by analyzing RNA
sequencing (RNAseq) data in datasets from The Cancer
Genome Atlas (TCGA) (cBioPortal) [23]. We found that
13% of ADC (N= 515) and 18% of SCC (N= 504) patients
carried transcriptional alterations in ALDH1A1, ALDH1A3,
or ALDH3A1 with a mutually exclusive tendency, sug-
gesting that these genes confer similar functional effects
(Fig. 1a). Overall, of the 158 NSCLC patients carrying
alterations in any of these ALDH isoenzymes, 86% har-
bored either gene ampliﬁcation or mRNA upregulation. The
transcriptional alterations observed in these isoenzymes
reﬂect the protein-level differences reported in Human
Protein Atlas platform in normal vs. tumor tissue, changing
from undetected or low staining in normal pneumocytes to
moderate or intense staining in tumor tissues [24] (Fig. 1b).
Cytotoxic chemotherapy retains a major role in the
management of advanced NSCLC [25]. Chemotherapy can
be used before surgery to reduce the tumor size (neoadju-
vant chemotherapy), after surgery in resected stage II and III
NSCLCs or in stage III and IV lung cancers that cannot be
removed surgically. Given the reported association of high
ALDH activity with tumor-initiating cells and chemother-
apeutic drug resistance [11, 13, 15], we next investigated
the inﬂuence of ALDH1A1, ALDH1A3, and ALDH3A1
mRNA expression on the survival of patients treated with or
without chemotherapy, according to data in public NSCLC
datasets from the TCGA and Gene Expression Omnibus
(GEO) databases.
Patients with noncancer-related death, incomplete
resection (R1), or missing clinical/pathological information
were generally excluded from the analysis. We ﬁrst ana-
lyzed the subset of patients with resected tumors who did
not receive neoadjuvant chemotherapy; these patients were
commonly early-stage patients. Overall survival (OS) ana-
lysis of 241 eligible patients revealed that patients with high
ALDH1A3 or ALDH3A1 expression had signiﬁcantly worse
survival than those with low ALDH1A3 or ALDH3A1
expression (P= 0.005 and P= 0.032, log-rank test; Fig. 1c
left, Table 1). We next evaluated OS in the subset of
patients who received chemotherapy as primary therapy.
Analysis of the 90 patients meeting these criteria showed
poor prognosis in the group of patients with high ALDH1A3
and ALDH3A1 expression (P= 0.031 and P= 0.005, log-
rank test; Fig. 1c right, Table 1), suggesting that ALDH1A3
and ALDH3A1 may affect not only early-stage patient
prognosis but also the tumor response to chemotherapy.
For ALDH1A1, and only in the cohort treated with
chemotherapy, patients with high ALDH1A1 expression
showed shorter median OS times than patients with low
ALDH1A1 expression (37 vs. 53 months, respectively;
Fig. 1c right, Table 1). Though this trend was not statisti-
cally signiﬁcant (P= 0.16), the tendency in the data was
consistent with that in a previous study reporting a sig-
niﬁcant correlation between high ALDH1A1 expression
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and poor prognosis in patients with advanced NSCLC
treated with induction chemotherapy [26].
ALDH1A1 has been associated with CSC populations in
many tumor types [27]. Consistent with this observation, in
patients with available tumor-grade characterization data
and independent of treatment regimen (N= 588), we found
survival differences based on ALDH1A1 expression and the
histological grade of NSCLC (Fig. 1d, Table 1). While high
ALDH1A1 expression was associated with prolonged sur-
vival of patients with well-differentiated tumors, an inverse
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trend toward worse OS with high ALDH1A1 expression
was seen in patients with moderate- and poorly differ-
entiated tumors.
To verify whether the expression of ALDH1A1,
ALDH1A3, or ALDH3A1 was related to other clin-
icopathological variables, a crosstab was subsequently
generated (Table 2). We found no statistically signiﬁcant
associations between the expression of ALDH1A1,
ALDH1A3, or ALDH3A1 and age, sex, or tumor size.
Interestingly, high expression of ALDH1A1 was associated
with nonsmoking status and lung squamous carcinoma.
High ALDH1A3 also showed a signiﬁcant association with a
history of no tobacco use and was associated with the ADC
histological type, early-stage tumors and tumors without
lymph node metastasis. ALDH3A1 was highly expressed in
lung SCC and in well- and moderately differentiated
tumors.
NSCLC cells are sensitive to DIMATE-mediated
inhibition of class 1 and class 3 ALDH activity
To evaluate the possible effects of inhibiting ALDH1A1,
ALDH1A3, and ALDH3A1 isoenzymes, we used 14
NSCLC cell lines with different oncogenic driver alterations
and the noncancerous cell line BEAS-2B for comparison. In
all cell lines, the transcriptional proﬁles of ALDH1A1,
ALDH1A3, and/or ALDH3A1 showed mRNA upregulation
across the different NSCLC lines and compared to BEAS-
2B cells (Fig. S1a, b). These differences were reﬂected at the
protein level and encompassed both the high expression and
mutually exclusive pattern observed for the three ALDH
isoenzymes in the patient cohort (Figs. 1a and 2a), and in
NSCLC tumor tissues vs. normal cells (Figs. 1b and 2a).
We previously showed that 4-dimethylamino-4-methyl-
pent-2-ynthioic acid S-methyl ester (DIMATE) is an
enzyme-activated and irreversible inhibitor of class 1 and
class 3 ALDHs [20, 28, 29]. Using biochemical assays, we
demonstrated that DIMATE efﬁciently suppresses ALDH1
and ALDH3 enzymatic activities in an expanded panel of
26 NSCLC cell lines that included the 14 NSCLC cell line
panel and 12 primary cell lines from patient-derived xeno-
grafts (Fig. 2b). In addition, DIMATE induced a signiﬁcant
dose-dependent reduction in viability in 19 of the 26
NSCLC cell lines tested (≥50%, P < 0.001; Fig. 2c, Table
S1). BEAS-2B cells, which were used as normal counter-
parts, and showed relatively low ALDH1A3 protein levels
and undetected ALDH1A1 and ALDH3A1 levels, were
highly resistant to DIMATE-induced cell death (half max-
imal inhibitory concentration (IC50)= ~50 µM) (Fig. 2a, c).
Overall, the effect of DIMATE on NSCLC cell viability and
the endogenous ALDH activity in untreated cells were
positively correlated, suggesting speciﬁc interaction of the
drug with its target (Fig. 2d). We found no relationships
between the cellular response to DIMATE and EGFR- or
KRAS-mutated genotypes (Fig. 2e).
HNE-protein adduct accumulation and redox
imbalance are the primary causes of DIMATE-
induced cell death in vitro
The lung ADC cell lines H1650 and H1975 were selected
for further analysis given their resistance to EGFR-targeted
therapies and their high sensitivity to DIMATE (IC50=
1.36 µM and IC50= 1.62 µM, respectively). In these cells,
DIMATE induced a time-dependent increase in caspase 3/7
activity and apoptotic cell death. (Fig. 3a and S2a).
DIMATE also readily caused accumulation of hydro-
xynonenal (HNE) and malondialdehyde (MDA), two
apoptogenic aldehydes that are detoxiﬁed by ALDH1 and
ALDH3, over time (Fig. 3b and S2b) [3]. This ﬁnding
suggested a relationship between the formation of new HNE
and MDA adducts and the onset of apoptosis. As HNE and
MDA accumulated, cells exhibited increased levels of
reactive oxygen species (ROS), particularly H2O2 (Fig. 3c,
d), and a rapid drop in intracellular levels of reduced GSH, a
crucial molecule for the detoxiﬁcation of H2O2 (Fig. 3e)
[30]. GSH also participates in the elimination of HNE
through the formation of GSH-HNE conjugates that are
exported from cells [31]. Accordingly, after 48 h of expo-
sure to the inhibitor and following the accumulation of
4-HNE, total intracellular GSH levels were decreased by
almost 50%, while GSH increased in the extracellular media
(Fig. 3e). Moreover, HNE coimmunoprecipitation com-
bined with mass spectrometry analysis revealed that GSH
S-transferase omega-1 (GSTO1) associated with HNE in
DIMATE-treated cells (Table S2). GSTO1 catalyzes
nucleophilic conjugation of GSH with a wide spectrum of
electrophiles, including HNE, when the cellular levels of
HNE are abnormally elevated [32]. Thus, depletion of GSH
Fig. 1 Expression of ALDH genes impacts the survival of NSCLC
patients. a Frequencies of ampliﬁcation (red bar), deletion (blue bar),
and mRNA upregulation (empty bar) for ALDH1A1, ALDH1A3, and
ALDH3A1 in lung adenocarcinoma and lung squamous cell carcinoma,
based on analysis of TCGA data (GISTIC2 analysis, cBioPortal). The
percentages shown indicate the overall rates of gene ampliﬁcation,
upregulation and/or deletion in each subtype of NSCLC. The vertical
aligned bars indicate samples from the same patient. b Representative
protein expression proﬁle for ALDHs based on immunohistochemistry
using tissue microarrays. The ﬁgure shows normal pneumocytes
exhibiting negative or low expression of ALDH1A1, ALDH1A3, and
ALDH3A1 vs. medium to high protein expression in lung cancer. The
images were obtained from the tissue section of the Human Protein
Atlas project [24]. The annotated protein expression includes an eva-
luation of the staining intensity and percentage of stained cells. c Flow
diagram summarizing the patient inclusion and exclusion criteria and
Kaplan–Meier survival curves based on ALDH1A1, ALDH1A3, and
ALDH3A1 expression. The vertical symbols represent censored cases.
d Prognostic impact of ALDH1A1 expression on OS according to
tumor grade.
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could result from active cellular efﬂux of reduced GSH-
HNE adducts.
In addition to GSTO1, other proteins were identiﬁed to
associate with HNE in DIMATE-treated cells (Table S2).
These proteins included L-lactate dehydrogenase, pyruvate
kinase isoenzymes M1/M2, malate dehydrogenase,
succinyl-CoA ligase, electron transfer ﬂavoprotein and
septin-7, which are involved in several cellular events,
including energy metabolism, redox homeostasis and cell
cycle progression.
Western blot analysis of the catalytic subunit of gluta-
mate cysteine ligase (GCLC), the rate-limiting enzyme in
GSH biosynthesis, revealed cleavage of GCLC in
DIMATE-treated cells and correlated temporally with the
induction of caspase 3/7 activity (Fig. 3f, a). The observed
size of the cleaved GCLC fragment was 60 kD, the same as
Table 2 Associations between
ALDH1A1, ALDH1A3, and
ALDH3A1 expression and
clinicopathological parameters.
Parameters (N) ALDH1A1 ALDH1A3 ALDH3A1
High/Low P value High/Low P value High/Low P value
Age 0.06 0.06 0.75
<65 (1042) 584/458 625/417 596/446
≥65 (960) 497/463 536/424 556/404
Sex 0.33 0.79 0.1
Male (1393) 729/664 708/685 814/579
Female (816) 409/407 420/396 447/369
Histology 2.80E−13* 2.20E−16* 2.69E−16*
Adenocarcinoma (1381) 625/756 859/522 711/670
Squamous (917) 558/359 410/507 629/288
Smoking history 1.20E−03* 1.44E−05* 0.61
Nonsmoker (245) 159/86 192/53 152/93
Smoker (993) 529/464 635/358 596/397
Grade 0.29 0.8 2.06E−03*
I–II (384) 207/177 274/110 248/136
III-IV (321) 186/135 232/89 170/151
Stage 0.29 3.53E−03* 0.90
I (757) 410/347 473/284 492/265
II-III-IV (476) 243/233 257/219 307/169
Lymph node affected 0.19 7.16E−03* 0.08
No (690) 341/349 432/258 387/303
Yes (576) 306/270 280/296 294/282
Tumor size 0.57 0.7 0.53
≤3 cm (368) 195/173 212/156 209/159
>3 cm (790) 404/386 465/325 432/358
N number of patients.
*P < 0.05.
Table 1 Median OS times of NSCLC patients according to the expression of ALDH1A1, ALDH1A3 and ALDH3A1.
Median overall survival (months)
Gene expression NSCLC nontreated with neoadjuvant
therapy (N= 241)
NSCLC treated with chemotherapy
(N= 90)
Grade I
(N= 201)
Grade II
(N= 310)
Grade III
(N= 77)
ALDH1A1Low 75 53.3 32.6 62 77.6
ALDH1A1High 95 (P= 0.130) 37 (P= 0.160) 79 (P= 0.001) 36 (P= 0.062) 32 (P= 0.064)
ALDH1A3Low 106 62 74 78.9 75.7
ALDH1A3High 68 (P= 0.005) 36 (P= 0.031) 48 (P= 0.139) 44.4 (P= 0.0522) 56.8 (P= 0.280)
ALDH3A1Low 96 77.6 68.6 96.1 65
ALDH3A1High 70.6 (P= 0.032) 32 (P= 0.005) 52 (P= 0.282) 65.2 (P= 0.062) 26.9 (P= 0.05)
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Fig. 2 DIMATE affects the viability of NSCLC cells independent
of their genetic background. a Immunoblots showing the amounts of
ALDH1A1, ALDH1A3, and ALDH3A1 in normal human bronchial
epithelial BEAS-2B cells and 14 NSCLC cell lines. GAPDH was used
as the loading control. b Representative changes in ALDH1 and
ALDH3 activity in an expanded panel of 26 NSCLC cell lines,
including the cell lines in a and 12 xenograft-derived NSCLC primary
cell lines (LXA), untreated or treated with the indicated dose of
DIMATE. Data are plotted in increasing order according to the
registered endogenous ALDH activity for each NSCLC cell line, i.e.,
from lower to higher mean values. A continuous connecting line was
drawn to better illustrate the inhibition of the signal in the presence of
DIMATE. ALDH activity was measured using a ﬂuorometric enzy-
matic assay and two substrate probes (SEF0025 and SEF0013) with
preferential afﬁnity for ALDH class 1 and ALDH class 3 molecules,
respectively (see the “Materials and methods” section for experimental
details). c Dose-response curves for cell viability in the panel of 26 cell
lines treated for 72 h with increasing doses of DIMATE. DIMATE-
sensitive NSCLC cell lines are grouped in the upper plot; resistant cell
lines, including the normal BEAS-2B line, are presented in the middle
plot; and xenograft-derived NSCLC cells (LXA) are grouped in the
lower plot. The error bars indicate the SDs (N= 4). d Graph showing
the Pearson correlation between endogenous cellular ALDH1 activity
and the IC50 values of DIMATE in the NSCLC cells in c. e Graphs
showing the IC50 values of DIMATE in the NSCLC cell lines
according to the mutational status. The horizontal bars indicate the
mean values.
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that reported for the longer fragment resulting from caspase-
3-mediated processing of GCLC [33].
Next, we investigated whether maintaining intracellular
levels of GSH could impact DIMATE sensitivity.
DIMATE-induced apoptosis was dose-dependently inhib-
ited by GSH-monoethyl ester (GSH-MEE), a membrane-
permeable GSH analog (Fig. 3g). Similarly, N-acetyl
cysteine (NAC), a synthetic precursor of intracellular
cysteine and GSH, dose-dependently improved cell viability
(Fig. 3h), conﬁrming the importance of GSH depletion
during the cellular response to DIMATE.
DIMATE suppresses tumor growth in an orthotopic
human lung cancer xenograft model
To evaluate the anticancer activity of DIMATE in vivo, we
used an orthotopic model of lung cancer. H1975/Luc cells
were surgically inoculated into the lung parenchyma of
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athymic mice. The implanted cells formed primary nodules
in the lung, which expanded with time into the contralateral
lung and mediastinal tissues. After 3 weeks of treatment
with 14 mg/kg and 28 mg/kg DIMATE, the biolumines-
cence signal was reduced by 18% and 64%, respectively,
compared to that in control mice (P= 0.33; P < 0.01) (Fig.
4a). Consistent with this ﬁnding, the computed tomography
(CT) images showed 27% and 79% tumor growth inhibition
in animals administered 14 mg/kg and 28 mg/kg DIMATE,
respectively, compared to control animals (P= 0.30 and
P < 0.005; Fig. 4b).
Histopathological analysis of lung tissues corroborated
neoplastic proliferation, with large, solid glandular growth, and
numerous pleomorphic cells (Fig. 4c). Notably, tumor necrosis
was dose-dependently enhanced in DIMATE-treated animals
(Fig. 4d). According to clinicopathological parameters and
associated pathological events in other organs and tissues, we
found no apparent toxic effects of DIMATE in treated animals.
Alteration of the tumor redox balance enhances the
sensitivity of NSCLC cells to DIMATE
In our panel of 26 NSCLC cell lines expressing ALDH class
1 and/or 3 molecules, cells with high ROS levels and
concomitant low to moderate GSH levels were signiﬁcantly
more susceptible to DIMATE-induced cell death (average
IC50= 4.05 ± 3.83; P < 0.001) than cells with either low
ROS levels or the highest GSH levels in the cohort (average
IC50= 30.40 ± 11.48) (Fig. 5a). Consistent with this ﬁnd-
ing, the endogenous ROS:GSH ratio had a good predictive
ability to discriminate DIMATE-sensitive from DIMATE-
resistant cells (AUC= 0.93; Fig. 5b).
To verify that DIMATE responses are inﬂuenced by the
cellular redox state, we investigated the effect of two agents
that inhibit the synthesis of GSH: L-buthionine-sulfoximine
(BSO), an irreversible inhibitor of gamma-glutamylcysteine
synthetase [34] and bis-chloroethylnitrosourea (BCNU), a
GSH reductase inhibitor [35, 36], in H460 cells that are
resistant to DIMATE (IC50= 46.5 µM) and possess high
GSH levels (136 µmol/106 cells). While 15 µM DIMATE,
100 µM BSO, or 50 µM BCNU alone did not affect cell
viability, the growth of cells treated with a combination of
DIMATE and either BSO or BCNU decreased by
approximately twofold (P < 0.001; Fig. 5c), accompanied
by a signiﬁcant increase in the apoptosis rate from 11% in
cells treated with single agents to 36 and 44% in cells
receiving DIMATE in combination with BSO or BCNU,
respectively (P < 0.001; Fig. S3a).
Using a different approach to induce cellular redox
imbalance, the cell lines HCC827, Hop62, and H2122,
which showed poor responses to DIMATE and low endo-
genous levels of ROS, were exposed to pyocyanin (PCN).
PCN induces oxidative stress partially due to its ability to
increase intracellular H2O2 and superoxide levels [37]. In
cells treated with noncytotoxic concentrations of PCN,
DIMATE sensitivity was increased by approximately four-
to ﬁvefold (Fig. 5d and S3b).
Next, we validated that the cellular redox state determines
the response of NSCLC cells to inhibition of ALDH 1 and 3
by genetically reducing the redox capacity in two NSCLC
cell lines, H460 and HCC827. Cells were infected with
tetracycline (Tet)-inducible system expressing either non-
targeting short hairpin RNA (shRNA) control, shRNA tar-
geting GCLC (in H460 cells) or shRNA targeting catalase
(CAT) (in HCC827 cells) (Fig. S4a, b). GCLC knockdown
decreased the intracellular levels of endogenous GSH by
approximately half in H460 cells (Fig. S4c) without affect-
ing cell viability (Fig. S4d), thus establishing a system with
low GSH redox capacity. In HCC827 cells, catalase down-
regulation did not result in a direct increase in intracellular
H2O2, as expected (data not shown) [38]; however, under
treatment with exogenous H2O2 (100 µM), viability was
signiﬁcantly compromised only in catalase-depleted
HCC827 cells (Fig. S4e), conﬁrming that the capacity of
these cells to clear H2O2 through catalase-mediated degra-
dation was decreased. Catalase downregulation did not
impact the viability of HCC827 cells (Fig. S4f).
In both H460 and HCC827 cells, transient knockdown of
their corresponding highest-abundant ALDH class 1 mole-
cule (ALDH1A1 in H460 and ALDH1A1 and ALDH1A3
in HCC827 cells) resulted in a compensatory increase in
ALDH3A1 protein expression (Fig. S5a, b) but did not
Fig. 3 DIMATE elicits GSH depletion and oxidative stress-
mediated apoptosis. a Bioluminescence measurements of caspase
3/7 activity in cells treated with 5 µM DIMATE at the indicated times.
The pancaspase inhibitor Z-VAD-fmk was used as the negative control
to conﬁrm the speciﬁcity of the DIMATE-induced signal. Data are
expressed as relative light units (RLU). Error bars ± SEM. (N= 3). b
Immunoblots showing the accumulation of HNE adducts over time in
H1650 and H1975 cells treated as described in a. c Total intracellular
ROS levels in H1650 and H1975 cells exposed to 5 µM DIMATE for
the indicated times. Error bars ± SD (N= 3). d Quantiﬁcation of H2O2
in H1650 and H1975 cells exposed to DIMATE for the indicated
times. The values are the averages of two independent experiments. e
Time course quantiﬁcation of intracellular and extracellular GSH in
H1650 and H1975 cells treated with 5 μM DIMATE for the indicated
times. The results are expressed relative to untreated controls and are
shown as the means ± SDs. (N= 2). f Expression of full length and
cleaved GCLC, as assessed by immunoblotting. GAPDH was used as
the loading control. g Caspase 3/7 activity in H1650 and H1975 cells
treated with 5 μM DIMATE for 12 h in the presence of increasing
concentrations of GSH-MEE (left axis). The right axis indicates the
percentage of cell viability determined simultaneously for the same
cells. The mean ± SD is shown (N= 3). h Graphs indicating the per-
centage of apoptotic H1650 and H1975 cells treated with DIMATE as
described in g in the presence of various concentrations of the anti-
oxidant NAC. Cell death was assessed by ﬂow cytometry. The error
bars indicate the SDs (N= 3); *P < 0.01, **P < 0.001.
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signiﬁcantly affect cell viability (Fig. S5c, d). Only simul-
taneous knockdown of ALDH1/ALDH3A1 followed by
doxycycline induction of shRNA targeting GCLC in H460
cells or catalase in HCC827 cells signiﬁcantly reduced cell
viability by 81.5% and 70.5%, respectively (Fig. 5e–g).
Collectively, these data suggest that NSCLC cells with high
expression of class 1 and/or class 3 ALDHs and poor
responses to simultaneous inhibition of these isoenzymes
Fig. 4 Tumor growth-inhibitory effect of DIMATE in orthotopic
H1975 xenografts. a Representative bioluminescence imaging of
tumor growth in H1975/luc xenografts treated with DIMATE or
vehicle control on day 21 of treatment. The lower graph shows the
quantiﬁcation of tumor growth as the average photon ﬂux emitted from
each group at different time points. **P < 0.001 (28 mg/kg DIMATE
group vs. control group). b Representative micro-CT images showing
the lung anatomy of mice with orthotopic H1975 xenografts treated at
two different concentrations of DIMATE as described in a. Macro-
scopic tumor lesions in the lungs are indicated with arrows. The lower
graph represents the tumor volume calculated from CT scans. Error
bars ± SD (N= 6). c Representative images of lungs harvested at
necropsy and stained with hematoxylin and eosin (H&E) (×20 mag-
niﬁcation). d Quantiﬁcation of tumor necrosis by densitometry. The
boxes extend from the 25th to the 75th percentile; the lines indicate
median values, and the whiskers indicate the range of values.
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could be sensitized by combining this inhibition with other
compounds that affect cellular redox status.
Synergistic effect of DIMATE and CDDP in the
orthotopic mouse model of NSCLC
CDDP-based chemotherapy is indicated as a ﬁrst-line
treatment for NSCLC, though, responses to this drug are
generally moderate [25]. The CDDP action mechanism
includes the generation of nuclear DNA adducts together
with its ability to increase total ROS by a mechanism that
appears independent of nuclear DNA damage signaling
[39, 40]. To further conﬁrm the hypothesis that DIMATE
treatment beneﬁts from treatment with drugs affecting redox
homeostasis, we evaluated the effectiveness of combining
DIMATE with CDDP in vitro and in vivo.
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In vitro, the extent of synergism (combination index (CI)
values) obtained for DIMATE and CDDP at 50–95% drug
effect (Fa) levels differed among the four resistant cell lines
tested (HCC827, Hop62, H2122, and H460), but the com-
bination showed stronger synergy at higher doses (Fa >
0.30, CI < 1) in all cell lines (Fig. 6a and Table S3).
Via a different approach and in HCC827 cells, which are
resistant to both DIMATE and CDDP (IC50= 24 and
15 µM, respectively), responses to DIMATE were com-
pared among cells with low endogenous levels of ROS and
cells with moderate and high levels of ROS induced by
CDDP treatment. (Fig. S6a). The extent of apoptosis
induced by DIMATE was proportional to the increase in the
ROS level in the three different cell populations; the
apoptosis rates were ~44%, 79% and 98% in cells with low,
moderate and high ROS levels, respectively (Fig. S6a). No
differences in ALDH1A1, ALDH1A3 and ALDH3A1
protein expression were observed between untreated and
CDDP-treated cell subpopulations (Fig. S6b).
To evaluate the beneﬁt in a preclinical setting, the efﬁ-
cacy of DIMATE plus CDDP was investigated in vivo in an
HCC827 orthotopic lung cancer model. Mice receiving
combination therapy showed rapid tumor regression and
signiﬁcantly higher tumor growth inhibition (P < 0.001)
than control mice and mice receiving DIMATE or CDDP as
monotherapy (Fig. 6b). Consistent with this result, histo-
pathological examination of pulmonary tumor tissues
showed the highest necrotic density in animals treated with
DIMATE and CDDP in combination (0.98 for the combi-
nation vs. 0.11 and 0.24 for DIMATE and CDDP alone,
respectively; Fig. 6c, d). Tumor necrosis was not evident in
the controls.
Discussion
The involvement of ALDH in tumor initiation, therapeutic
resistance and malignant behavior has become a popular
topic in cancer research (reviewed in [11–16]). Previous
studies reported a signiﬁcant correlation of class 1 ALDHs
with poor clinical outcome in patients with NSCLC
[5, 26, 41]. Although these initial studies could not separate
the contribution of individual isoenzymes, the results
underscored the clinical potential of ALDHs in lung cancer.
More recently, ALDH1A1 and ALDH3A1 were reported to
be highly expressed in NSCLCs, and both isoenzymes were
found to be overexpressed in putative lung epithelial stem
cell niches in tumors compared with normal lung tissues
[6, 7]. These observations have generated interesting spec-
ulation on the relationship of ALDHs to lung cancer
[10, 12].
Here, we described ALDH1A1, ALDH1A3, and ALDH3A1
gains and mRNA upregulation to be associated with prog-
nosis in lung ADC and SCC histological subgroups and
provided supporting evidence that ALDH1A3 and
ALDH3A1 could be a prognostic marker in NSCLC patients.
In addition, we found that ALDH1A3 expression was asso-
ciated with ADC histology, while ALDH3A1 was strongly
associated with squamous histology. Consistent with our
results, Shao et al. [9] found that ALDH1A3 was highly
expressed in early-stage tumors and patients with a non-
smoking history. We also revealed a signiﬁcant association of
high ALDH1A1 with never-smoker status, identifying
ALDH1A1 and ALDH1A3 as possibly related to new risk
factors in the ~10–20% of lung cancers occurring in never
smokers [42]. Interestingly, normal pneumocytes of smokers
are reported to exhibit increased expression of ALDH1A1
compared with those of nonsmokers [6]. These data, with our
ﬁndings, support the key role that ALDH1A1 plays in the
response to xenobiotics (likely, tobacco, chemotherapy and
other chemicals) and invite a careful interpretation of studies
comparing ALDH1A1 expression in lung tumor vs. normal
lung tissues considering smoking patterns and exposure to
other toxic agents. Consistent with this observation and in
partial contrast with three earlier studies reporting ALDH1A1
as a predictor of poor prognosis in NSCLC [7, 43, 44], our
results using more restrictive exclusion criteria indicated that
high levels of ALDH1A1 determine signiﬁcantly better OS in
Fig. 5 The response of NSCLC to ALDH1 and ALDH3 inhibition
is synergistically enhanced by ROS-inducing agents or inhibitors
of the GSH cellular antioxidant system. a Three-dimensional plot
showing the distribution of IC50 values for DIMATE and the total
intracellular GSH and ROS levels in each of the 26 NSCLC cell lines.
The square highlights cells showing high sensitivity to DIMATE,
which are also the cells with high ROS levels and low to moderate
GSH levels. b ROC curves for the response of NSCLC cells to
DIMATE vs. ROS levels, total intracellular GSH levels and the ROS:
GSH ratio. (AUC= 0.67, 0.56, 0.93, respectively). ROC receiver
operating characteristic; AUC area under the ROC curve. c Relative
viability of H460 cells treated with 15 µM DIMATE, 100 µM BSO or
50 µM BCNU alone and in the indicated combinations as a function of
time. The drug vehicle was used as the control. A signiﬁcant decrease
in viability was observed in H460 cells treated with DIMATE plus
BSO or DIMATE plus BCNU compared to cells treated with the
control or compound alone (P < 0.001; t-test). The data are expressed
as the mean fold changes in cell number relative to day 1 ± SDs (N=
3). d Dose-response curve for the viability of HCC827 cells exposed
for 48 hours to DIMATE in the presence or absence of PCN. The IC50
values for the different conditions are provided in the graph. The inner
panel shows that 40 μM PCN exhibited no cytotoxicity at the indicated
incubation times. The error bars indicate the SD (N= 4). e Schematic
representation of the strategy used to evaluate the viability of H460
and HCC827 cells when transient depletion of ALDH1 and/or ALDH3
was combined with the reduction in redox capacity induced by GCLC
shRNA or CAT shRNA, respectively. f, g Viability of stable H460
cells expressing dox-inducible GCLC shRNA and HCC827 cells
expressing dox-inducible CAT shRNA as described in e with ALDH1
or ALDH3 depletion as indicated in the x axis at the 96-h time point.
The data are expressed as percentages relative to control cells. The
error bars indicate the SDs. (N= 3); **P < 0.005.
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patients with well-differentiated tumors and provide an
overall minimal beneﬁt in patients with early-stage tumors
and no neoadjuvant treatment. Although this protective effect
of ALDH1A1 was reversed in moderately and poorly dif-
ferentiated tumors and in chemotherapy-treated patients, this
trend was nonsigniﬁcant. ALDH1A1 is likely to be linked to a
generally protective role in xenobiotic clearance in the lungs.
These observations place the ALDH1A1 in a different cate-
gory of ALDHs.
DIMATE is an irreversible inhibitor of class 3 and class
1 ALDHs (except ALDH 2) [28, 29]. Because of this dual
effect, we selected this compound to investigate the phar-
maceutical effect of simultaneous inhibition of ALDH 1 and
3 in NSCLC. Our study showed that DIMATE causes the
accumulation of aldehydes and aldehyde-protein adducts
that might compromise protein function and fate in cancer
cells [31]. In parallel, intracellular levels of GSH decreased
as GSH was engaged in active-enzyme mediated detox-
iﬁcation of the accumulated aldehydes. These early events
triggered an ampliﬁcation cycle of oxidative stress carried
by (i) enhanced formation of ROS, particularly H2O2, which
might be the source of new aldehydes due to lipid peroxide
Fig. 6 Synergistic inhibitory effect of DIMATE and CDDP in
NSCLC cells. a CI curve analysis (Chou–Talalay plot) for DIMATE
plus CDDP in HCC827, H460, Hop62, and H2122 cells, indicating
synergy at medium and high doses. CI values less than, equal to, or
greater than 1 indicate synergy, additivity, or antagonism, respectively.
The effect level (Fa) indicates the fractional inhibition for each CI. b
Representative micro-CT images showing the lung anatomy of mice
with orthotopic HCC827 xenografts treated with either DIMATE,
CDDP or DIMATE plus CDDP. Macroscopic tumor lesions in the
lungs are indicated with arrows. The lower graph shows the tumor
volumes calculated from CT scans at the indicated time points. c
Representative images of pulmonary tumors at necropsy stained with
H&E (20X magniﬁcation). d Quantiﬁcation of tumor necrosis within
tumor sections by densitometry.
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attack, [32] and (ii) GCLC cleavage, likely mediated by
caspases, which would affect de novo synthesis of GSH,
further enhancing the intracellular redox imbalance that
precipitates cell death [45]. We demonstrated the in vivo
efﬁcacy of DIMATE in lung cancer orthotopic models.
Notably, DIMATE can increase sensitivity to ROS-
inducing agents, a criterion met by existing mainstay can-
cer therapies [46]. Speciﬁcally, we showed that CDDP and
DIMATE were synergistic at reduced doses, suggesting a
potential means for improving tumor responses to platinum-
based antineoplastic agents and avoiding the toxicities of
this drug class.
In conclusion, we show for the ﬁrst time the beneﬁt of
using dual inhibitors of ALDH1 and ALDH3 as redox-
disrupting agents in lung carcinomas and provide preclinical
support for their use as monotherapies or in combination
with other ROS-targeting drugs in NSCLCs, including
chemoresistant tumors.
Material and methods
Cell lines and cell culture
A panel of 26 human NSCLC cell lines and the cell line
BEAS-2B were obtained either from the American Type
Culture Collection or from the laboratory of Dr Yokota Jun
(Research Institute Germans-Trias Pujol, Spain), as detailed
in Supplementary Table S1. Twelve patient-derived lung
tumor xenograft cell lines (named LXA for Lung Xenograft
ADC) were obtained from Oncotest (Freiburg, Germany),
and are described in detail in Table S1. BEAS-2B cells were
cultivated in BEGMBronchial Epithelial Cell Growth
Medium (Lonza, Barcelona, Spain). The other cell lines
were propagated in RPMI-1640 medium supplemented with
10% FBS, 100 U/mL penicillin and 100 μg/mL streptomy-
cin. All cells were maintained in a humidiﬁed atmosphere
containing 5% CO2 at 37 °C.
Cell viability assays
Cells were seeded in 96-well plates and treated with serial
dilutions of DIMATE (0.01–100 µM) with or without PCN
(40 µM), BSO (100 µM), or BCNU (50 µM) for 12, 48, and
72 h and analyzed using alamarBlue dye (Thermo Fisher,
Saint Herblain, France). Drug responses were quantiﬁed by
the IC50 for each cell line and determined by nonlinear
regression analysis of log dose-response curves. The cutoff
value for DIMATE resistance was determined statistically
(greater than the geometric mean IC50+ SD). To reverse
DIMATE-induced cell death, cells were exposed to 10 µM
DIMATE in the presence of GSH-MEE at different con-
centrations (1–10 mM). Cell viability was measured using
the alamarBlue assay following the manufacturer’s
instructions (Thermo Fisher).
Immunoblotting
For protein expression analysis, cells were lysed in RIPA
buffer containing phosphatase and protease inhibitors
(Calbiochem, San Diego, CA, USA). Total protein extracts
were separated via SDS-PAGE and transfer to poly-
vinylidene diﬂuoride membranes (Bio-Rad electrophoresis
and Trans-Blot turbo transfer systems, Marnes-la-Coquette,
France). Immunodetection was performed using standard
protocols [47]. Antibodies used in these studies are listed in
Table S4.
Analyses using NSCLC cells
To analyze ALDH activity, cells incubated with ﬂuorescent
probes derived from propional (10 µM, SEF0025) and
benzoate (5 µM, SEF0013), two preferred substrates of
ALDH1 and ALDH3, respectively [20]. Enzymatic reac-
tions were performed in live cells at 37 °C for 30 min and
read immediately using an Appliskan ﬂuorescence micro-
plate reader (ex= 530 nm; em= 600 nm).
H2O2 was measured using an Amplex UltraRedﬂuoro-
metric assay (Invitrogen, Cailloux-sur-Fontaines, France),
and Caspases-3 and -7 activity was estimated using a
Caspase-Glo 3/7 assay (Promega, Charbonnieres-les-Bains,
France). The pancaspase inhibitor Z-VAD-fmk (50 µM) was
used as the experimental control.
Reduced and oxidized GSH levels were measured using
a GSH/GSSG-Glo assay kit (Promega) following the man-
ufacturer’s instructions. Acivicin (0.5 mM) was used to
block degradation of extracellular GSH. Protein titration
was performed with cell lysate by the BCA method after
both extracellular and intracellular GSH measurements.
Luminescence was read in a Synergy Mx luminometer
(BioTek, Winooski, VT, USA) with a 1-min lag time and a
0.5 s/well read time.
Small interfering RNA (siRNA) and shRNA assays
For transient experiments, cells were transfected with either
a scrambled siRNA or different siRNAs targeting
ALDH1A1, ALDH1A3, or ALDH3A1 obtained from
Invitrogen-Thermo Scientiﬁc (see Fig. S5e for sequences).
For inducible transcriptional downregulation, cells were
infected with the hu-GCLC or hu-CAT Tet-inducible len-
tiviral shRNA system (Dharmacon SMARTvector, Horizon,
Cambridge, UK). The control vector used was a non-
targeting DNA (Horizon). shRNA sequences are detailed in
Table S5. For shRNA expression, the culture medium was
supplemented daily with 5 mM doxycycline. Knockdown
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efﬁciency was evaluated by Wes, quantiﬁcation of intra-
cellular GSH levels and the cellular oxidative response to
H2O2.
CI analysis
DIMATE-CDDP interactions were analyzed using CI
curves and CompuSyn software made available by Chou
[48]. Cells were seeded in 96-well plates and treated with
different concentrations of DIMATE/CDDP in combination
using constant ratios for each drug. The drug effect level
(Fa) was monitored at 48 h using the alamarBlue assay as
described above.
In vivo orthotopic xenograft mouse model
The institutional Animal Care and Use Committee at Vall
d’Hebron Research Institute (VHIR, Barcelona, Spain)
approved all animal protocols described in this study.
Fireﬂy luciferase-labeled H1975 (H1975/Luc) or HCC827
cells (1 × 106) were surgically implanted into the lung par-
enchyma of female, athymic nude mice as previously
described [49]. Animals were complete randomized into the
following groups: control (N= 6), 14 mg/kg DIMATE
(N= 6), and 28 mg/kg DIMATE (N= 6) for H1975/Luc
xenografts; and control (N= 6), 28 mg/kg DIMATE (N=
6), 5 mg/kg CDDP (N= 6) and DIMATE/CDDP (N= 6)
for HCC827 xenografts. Mice were treated three times
weekly with intraperitoneal injections of vehicle control
and/or DIMATE and/or weekly with CDDP. Tumor growth
was monitored using a noninvasive imaging approach
involving luciferin injection (4 mg/mouse) and imaging
with an IVIS Spectrum instrument. In addition, tumor
growth was quantiﬁed by CT imaging.
Bioinformatic and statistical analyses
The following bioinformatic tools were used to analyze the
functions of ALDHs in NSCLC biological processes:
TCGA, cBioPortal [23], Oncomine [50, 51]; Human Protein
Atlas [24]; Kaplan–Meier plotter [52, 53] and GEO
[54, 55].
Kaplan–Meier plotter and the R program were used to
evaluate the clinical relevance of ALDHs by linking clinical
data to gene expression levels. Kaplan–Meier Plotter was
used to conﬁrm disease prognosis and OS times. Tran-
scriptome microarray datasets were downloaded from the
TCGA and GEO databases under the accession numbers
GSE8894 (N= 138), GSE19188 (N= 91), GSE3141
(N= 111), GSE31210 (N= 246), GSE4573 (N= 130),
GSE14814 (N= 133), GSE29013 (N= 55), GSE37745
(N= 196), GSE30219 (N= 293), GSE31908 (N= 30),
GSE43580 (N= 150), GSE50081 (N= 181), caArray
(N= 443), and TCGA (N= 133). All datasets were trans-
formed to a common scale and precision. Normalized raw
transcriptome data were subsequently reanalyzed to evaluate
the associations between ALDH1A1, ALDH1A3, and
ALDH3A1 expression and clinicopathological variables using
the nonparametric Fisher’s exact test. Analysis was performed
with the R program [56].
The ﬂow cytometric analysis, cell viability assay, and
in vivo tumor growth results were analyzed by a paired
t-test. P < 0.05 was considered statistically signiﬁcant.
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